Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06326736 Recruiting - Pancreatic Cancer Clinical Trials

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Start date: April 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.

NCT ID: NCT06323291 Recruiting - Pancreatic Cancer Clinical Trials

Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study

Start date: March 8, 2024
Phase: Early Phase 1
Study type: Interventional

This Pilot Study will evaluate a 12-week pilot program that offers digital health coaching for individuals with pancreatic cancer and their caregivers.

NCT ID: NCT06307080 Recruiting - Pancreatic Cancer Clinical Trials

Clinical Study of Multi-mode Thermal Ablation for the Treatment of Pancreatic Cancer With Liver Metastasis

Start date: October 8, 2023
Phase: N/A
Study type: Interventional

1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. 3. Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.

NCT ID: NCT06289803 Recruiting - Pancreatic Cancer Clinical Trials

The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Aim of the study: To evaluate the value of Probe Confocal Laser Endomicroscopy (PCLE) in surgery for pancreatic tumor. Methods: Patients who are diagnosed with pancreatic tumor based on preoperative radiographic findings and will undergo radical resection are included in this clinical study. PCLE will be used in surgery to identify tumor is malignant or not, and surgeons will decide procedures of surgery based on outcomes of PCLE. In this present study, clinical trials will be divided into two phases. In the first phase, based on the definitive postoperative pathologic diagnosis, characteristic imaging structures that were collected by PCLE will be identified and primary diagnostic imaging criteria for pancreatic cancer would be developed. In the second phase, this criterion will be used for rapid intraoperative diagnosis of pancreatic cancer and predicting status of resection margin. In addition, accuracy of PCLE will be verified based on postoperative pathologic reports.

NCT ID: NCT06270082 Recruiting - Colorectal Cancer Clinical Trials

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Start date: December 18, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.

NCT ID: NCT06256055 Recruiting - Colorectal Cancer Clinical Trials

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Start date: March 5, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802 (Circular mRNA encoding Anti-Mesothelin CAR-T) injection in patients with Mesothelin-positive advanced malignant solid tumors.

NCT ID: NCT06245330 Recruiting - Pancreatic Cancer Clinical Trials

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

Start date: July 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.

NCT ID: NCT06244771 Recruiting - Colorectal Cancer Clinical Trials

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

PROSPER
Start date: February 12, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

NCT ID: NCT06238479 Recruiting - Prostate Cancer Clinical Trials

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Start date: March 5, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

NCT ID: NCT06224387 Recruiting - Clinical trials for Non-small Cell Lung Cancer

CTS2190 Phase I /II Clinical Study in Patients

Start date: June 26, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types. The study drug, CTS2190, is a PRMT1 inhibitor administered orally. The study is planned to treat up to 224 participants.